Sana Biotechnology, Inc. develops ex vivo and in vivo cell engineering platforms to address the root causes of various diseases. The company's pipeline primarily targets therapeutic areas with significant unmet needs, including type 1 diabetes, B-cell mediated autoimmune diseases, and oncology. Key clinical and preclinical programs include UP421 and SC451, which are pancreatic islet cell therapies for diabetes, as well as CAR-T therapies like SC291 for B-cell malignancies. Operating out of facilities in Seattle, Cambridge, and South San Francisco, Sana differentiates itself through its fusogen technology for targeted in vivo gene delivery and its hypoimmune platform. These technologies aim to repair genes and replace damaged cells without relying on complex, patient-specific autologous manufacturing or requiring long-term immunosuppression.
